Daily Bio News Summary — 2026-09-24

Thursday’s harvest produced seventeen news items across five sources: BioSpace (6), Fierce Pharma (5), PR Newswire’s FDA feed (4), Fierce Biotech (1) and Pharmaphorum (1). The day was dominated by metabolic medicine — an FDA clearance and a market-share claim for Eli Lilly, a rebrand for Novo — plus a pivotal ophthalmology result for Merck, a mid-stage stumble for Acadia, and a long-term data package that Kyverna hopes converts into a first-in-class CAR-T approval.

Lilly opens a second metabolic front

The FDA cleared Eli Lilly’s once-weekly insulin, setting up another front in the company’s rivalry with Novo (BioSpace, 2026-09-23). A weekly basal insulin competes on the same convenience axis that has driven the GLP-1 franchise wars, and it lands in a diabetes market where Lilly is already the volume leader on the obesity side.

The same day, Lilly’s CEO said the company holds roughly 70% of the Medicare GLP-1 market, with the program reaching 700,000 seniors (Fierce Pharma, 2026-09-23). Put the two items together and the picture is of a company defending share on multiple fronts at once — injectable diabetes on one side, Medicare-covered obesity on the other.

Novo’s answer to that pressure is partly cosmetic: the Danish drugmaker is shortening its name to Novo as its new chief executive works to turn the company around (Pharmaphorum, 2026-09-24). Rebrands do not change pipelines, but they are the cheapest signal a board can send that a reset is underway.

Eye disease: a pivotal match and a marketing bet

Merck’s experimental eye drug matched Roche’s VEGF inhibitor in a head-to-head-style comparison, though safety concerns emerged in the data (BioSpace, 2026-09-24). Matching an entrenched competitor is the minimum bar for entry in a market where Roche’s franchise sets the standard; the safety signal is what will determine whether this becomes a commercial threat or a footnote.

Glaukos, meanwhile, is pursuing awareness rather than efficacy: the company tapped NBA champion Stephen Curry for a keratoconus campaign (Fierce Pharma, 2026-09-24). Keratoconus is exactly the kind of underdiagnosed condition where patient-facing campaigns move the funnel more than incremental clinical data do.

Opposite directions in CNS and autoimmune

Acadia Pharmaceuticals’ drug missed the mark in a mid-stage Alzheimer’s psychosis study, but the company said it saw enough signal to continue with a modified Phase 3 program (Fierce Biotech, 2026-09-24). Alzheimer’s psychosis sits in the same neuropsychiatric territory as the company’s approved Parkinson’s psychosis franchise, so a modified program rather than a full stop is a bet that the signal — not the endpoint — was the problem.

Kyverna went the other way with its durability package, saying long-term data support an FDA submission for its CAR-T therapy in a rare autoimmune disease (BioSpace, 2026-09-24). Durability is the open question for every autoimmune cell therapy: the field has shown it can produce responses, but not yet that it can do so once, durably and at a cost the system will pay.

A regulatory sweep: one vote, one designation, one recall

An FDA advisory committee voted in favor of approving GRAIL’s Galleri multi-cancer early detection test (PR Newswire FDA, 2026-09-23). MCED tests have struggled to clear the evidence bar for population screening, so a favorable adcomm vote is a meaningful procedural milestone for the category.

On the device side, the FDA granted breakthrough device designation to Glytec’s Glucommander Pediatrics, an insulin management technology for hospitalized newborns and infants (PR Newswire FDA, 2026-09-24). Neonatal glycemic control is a small, high-acuity niche with few purpose-built tools.

Two compliance items closed the regulatory picture: an Otsuka joint venture is recalling one lot of sodium chloride for intravenous use over a labeling issue (Fierce Pharma, 2026-09-24), and KVK-Tech said it completed an FDA REMS inspection with no observations (PR Newswire FDA, 2026-09-22). Recalls of a commodity IV fluid and clean inspections are the unglamorous majority of what regulators actually do.

China on both sides of the table

Eli Lilly signed a deal worth up to $3.25 billion with China’s InnoCare to develop new medicines (BioSpace, 2026-09-23) — the second China pact of the week after Roche’s up-to-$2 billion cardiometabolic discovery deal with Atavistik (BioSpace, 2026-09-23). Licensing into and out of China has become a routine component of Western pipelines rather than an exception.

At the policy level, China laid out plans to grow its biotech sector into a $522 billion powerhouse by 2030 (BioSpace, 2026-09-18). National targets and deal flow are two halves of the same story: the capital is following the capacity.

Manufacturing and patient-facing footprint

Cellares is testing its automated cell therapy manufacturing platform with a South Korean hospital, its second such test in Asia (Fierce Pharma, 2026-09-23) — a reminder that cell therapy economics are increasingly settled in the manufacturing suite rather than the clinic. Biogen, meanwhile, launched a kidney health campaign featuring Olympic gymnast Suni Lee (Fierce Pharma, 2026-09-24), the day’s second example of a drugmaker buying attention rather than data.

What this batch is NOT telling us

No oncology readouts of consequence, no IPO pricing, no layoffs, and no AI-native discovery mega-rounds — yesterday’s harvest carried the Enveda and Basecamp financings, and today’s agenda is clinical and commercial instead. It is also worth noting that every Endpoints News candidate in this batch was paywalled at parse time; rather than publish gated links, this summary carries the equivalent free-source reporting of the same stories (BioSpace, Fierce Biotech and PR Newswire’s FDA feed). Nothing in the list below is behind a subscription wall.

Reading order

If you only read five things:

1. Lilly’s weekly insulin clearance (BioSpace) — the next front in the metabolic franchise war.
2. Merck’s eye drug vs Roche (BioSpace) — the day’s most commercially consequential clinical result.
3. Kyverna’s durability data (BioSpace) — the autoimmune CAR-T field’s central open question.
4. The Galleri adcomm vote (PR Newswire FDA) — a procedural milestone for multi-cancer screening.
5. Lilly–InnoCare (BioSpace) — the week’s second China licensing deal, and a $3.25 billion one at that.

How to read the underlying articles

Each item in this summary corresponds to a markdown file in src/content/news/, where the sourceUrl field points at the original reporting and sourceName identifies the outlet. Where a story is company-specific, the news file carries a companyId that links to a profile in src/content/companies/.

The full list (17 items)

1. Novo Nordisk rebrands as Novo as new CEO charts turnaround (Pharmaphorum, 2026-09-24)
2. Glytec receives FDA breakthrough device designation for Glucommander Pediatrics, an insulin management technology for hospitalized newborns and infants (PR Newswire FDA, 2026-09-24)
3. Lakewood-Amedex Biotherapeutics announces first patient dosed in Phase 2a clinical trial of NU-3 for infected diabetic foot ulcers (PR Newswire FDA, 2026-09-24)
4. Otsuka venture yanks sodium chloride for IV over labeling issue (Fierce Pharma, 2026-09-24)
5. Glaukos taps Stephen Curry for keratoconus awareness campaign (Fierce Pharma, 2026-09-24)
6. Biogen springs kidney health campaign with gymnast Suni Lee (Fierce Pharma, 2026-09-24)
7. Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge (BioSpace, 2026-09-24)
8. Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare (BioSpace, 2026-09-23)
9. Acadia misses mark in Alzheimer’s but continues phase 3 program (Fierce Biotech, 2026-09-24)
10. Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data (BioSpace, 2026-09-24)
11. FDA Advisory Committee votes in favor of approval of GRAIL’s Galleri multi-cancer early detection test (PR Newswire FDA, 2026-09-23)
12. Lilly captures 70% of surging Medicare GLP-1 market, CEO says (Fierce Pharma, 2026-09-23)
13. Cellares tests automated cell therapy with South Korean hospital (Fierce Pharma, 2026-09-23)
14. Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs (BioSpace, 2026-09-23)
15. Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalry (BioSpace, 2026-09-23)
16. China plans to transform biotech sector into $522B powerhouse by 2030 (BioSpace, 2026-09-18)
17. KVK-Tech completes FDA REMS inspection with no observations (PR Newswire FDA, 2026-09-22)